UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 623

Sortiert nach

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Cancer science, 2016-09, Vol.107 (9), p.1179-1186

2016

Volltextzugriff (PDF)

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

Cancer science, 2007-12, Vol.98 (12), p.1817-1824

2007

Volltextzugriff (PDF)

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

The FEBS journal, 2010, Vol.277 (2), p.301-308

2010

Volltextzugriff (PDF)

Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer

Cancer science, 2022-03, Vol.113 (3), p.815-827

2022

Volltextzugriff (PDF)

Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial

The Journal of thoracic and cardiovascular surgery, 2019-09, Vol.158 (3), p.895-907

2019

Volltextzugriff (PDF)

A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer

The Journal of thoracic and cardiovascular surgery, 2022-01, Vol.163 (1), p.289-301.e2

2022

Volltextzugriff (PDF)

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

The New England journal of medicine, 2022-05, Vol.386 (21), p.1973-1985

2022

Volltextzugriff (PDF)

Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma

Journal of clinical oncology, 2011-08, Vol.29 (22), p.2972-2977

2011

Volltextzugriff (PDF)

Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201

The Journal of thoracic and cardiovascular surgery, 2013-07, Vol.146 (1), p.24-30

2013

Volltextzugriff (PDF)

Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer

The Journal of thoracic and cardiovascular surgery, 2014-05, Vol.147 (5), p.1604-1611.e3

2014

Volltextzugriff (PDF)

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

Archives of toxicology, 2015-08, Vol.89 (8), p.1227-1240

2015

Volltextzugriff (PDF)

Advances in Target Therapy for Lung Cancer

Japanese journal of clinical oncology, 2010-02, Vol.40 (2), p.101-106

Mitsudomi, Tetsuya

2010

Volltextzugriff (PDF)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy

Translational lung cancer research, 2020-12, Vol.9 (6), p.2618-2628

2020

Volltextzugriff (PDF)

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

The New England journal of medicine, 2010-10, Vol.363 (18), p.1734-1739

2010

Volltextzugriff (PDF)

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.1753-1765

2019

Volltextzugriff (PDF)

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

Lung cancer (Amsterdam, Netherlands), 2016-08, Vol.98, p.69-75

2016

Volltextzugriff (PDF)

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

Journal of thoracic oncology, 2020-05, Vol.15 (5), p.709-740

2020

Volltextzugriff (PDF)

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

JNCI : Journal of the National Cancer Institute, 2017-06, Vol.109 (6)

2017

Volltextzugriff (PDF)

Surgery for NSCLC in the era of personalized medicine

Nature reviews. Clinical oncology, 2013-04, Vol.10 (4), p.235-244

2013

Volltextzugriff (PDF)

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

Molecular cancer therapeutics, 2017-02, Vol.16 (2), p.357-364

2017

Volltextzugriff (PDF)

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-07, Vol.38 (19), p.2187-2196

2020

Volltextzugriff (PDF)

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors

Cancers, 2021-08, Vol.13 (16), p.4035

2021

Volltextzugriff (PDF)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations

Cells (Basel, Switzerland), 2021-06, Vol.10 (7), p.1590

2021

Volltextzugriff (PDF)

1 – 25 von 623

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(497)
Mit Volltextzugriff
(595)

Publikationsform

Sprache

Englisch
(541)
Japanisch
(241)
Deutsch
(1)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(361)
Life Sciences & Biomedicine
(355)
Humans
(338)
Oncology
(270)
Female
(189)
Lung Neoplasms - Genetics
(181)
Male
(178)
Lung Cancer
(168)
Lung Neoplasms - Pathology
(162)
Aged
(147)
Mutation
(147)
Biological And Medical Sciences
(146)
Middle Aged
(142)
Medical Sciences
(138)
Respiratory System
(135)
Lung Neoplasms - Drug Therapy
(118)
Adult
(115)
Pneumology
(103)
Tumors Of The Respiratory System And Mediastinum
(100)
Carcinoma, Non-Small-Cell Lung - Genetics
(90)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy

Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer

Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer

Utility of the Ba/F3 cell system for exploring on‐target mechanisms of resistance to targeted therapies for lung cancer

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial

A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma

Radiographically determined noninvasive adenocarcinoma of the lung: Survival outcomes of Japan Clinical Oncology Group 0201

Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Role of EGFR mutations in lung cancers: prognosis and tumor chemosensitivity

Advances in Target Therapy for Lung Cancer

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro

Clinical and pathologic features of lung cancer expressing programmed cell death ligand 1 (PD-L1)

IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival

Surgery for NSCLC in the era of personalized medicine

Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer

Perioperative Therapy for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations

Suchergebnisse filtern